We got featured in this week's FutureFemHealth newsletter discussing the evolving PCOS market -- read more here: https://lnkd.in/e3bhuRG4
Why haven't we 'solved' PCOS? Aside from the usual barriers in women's health (lack of funding, lack of research etc), PCOS has another set of interesting challenges on top. On paper it looks like one of the biggest opportunities in women's health - huge unmet need (affecting 10-13% of women globally), significant health risks, and high burdens for healthcare systems and the economy. Yet there's no cure and barely any disease-modifying treatments in the pipeline. In a new deep-dive for FutureFemHealth (out tomorrow), I'm exploring the PCOS space. I'll share a market map and outline the companies innovating in the space. But more than that, I'll be digging into why progress has been so slow for PCOS and (spoiler) why the system is the problem. In tomorrow’s newsletter, I’ll: 🔍 break down why PCOS has been so difficult to solve - from biological complexity to structural incentive problems. 🔍 map the emerging innovation landscape, from GLP-1s and hormone-targeting therapies to care platforms, diagnostics and supplements. 🔍 outline the key signals that will determine whether this becomes a real, scalable category - including reimbursement, data infrastructure and narrative shift. One big takeaway for me: PCOS needs to be understood and treated as a lifelong chronic condition (rather than only fertility or weight gain etc). 📩 If you're interested in where the market for PCOS is heading and want to read the full deep-dive tomorrow, you can subscribe here: 👉 www.futurefemhealth.com. 📌 **EDITED** to add: the deep dive is now live here: https://lnkd.in/emZpX7x9